Financial terms of the agreement have not been disclosed. Sanofi and GSK, which had first teamed up in April, confirmed in a statement that regulatory approval for their vaccine could be won by the first half of 2021 if clinical data was positive.

Britain has moved early in striking vaccine supply deals, and ministers have stressed the importance of securing supplies of a range of candidates.